Executive Summary
Assessing the non-target tissue biodistribution of lipid nanoparticle (LNP) delivered mRNA therapeutics in non-human primate (NHP) models is a mandatory step for de-risking clinical development. While LNPs are designed for specific cell or tissue delivery, a significant fraction of the administered dose invariably distributes systemically. This profile directly informs the toxicology program, helps establish a therapeutic window, and is a core component of a successful Investigational New Drug (IND) application. Franklin Biolabs provides GxP-compliant NHP biodistribution studies, leveraging quantitative PCR (qPCR) and advanced histology to generate precise, submission-ready data within an 18-24 month IND timeline.
Why is the NHP model highly relevant for LNP-mRNA biodistribution assessment?
The NHP model provides the most translationally relevant data due to its immunological and physiological similarity to humans. The NHP complement system, lipid metabolism, and organ-level perfusion dynamics closely mimic human responses to LNP administration, yielding predictive data on potential non-target accumulation in organs like the spleen, liver, and bone marrow. This fidelity is not achievable in rodent models.
Which quantitative methods are used to measure mRNA and LNP distribution?
We employ a multi-faceted approach. The primary method is reverse transcription quantitative PCR (RT-qPCR) to measure mRNA payload concentration in tissues. This is complemented by techniques like Locked Nucleic Acid in situ Hybridization (LNA-ISH) for cellular localization and liquid chromatography-mass spectrometry (LC-MS) to quantify specific lipid components of the LNP carrier itself.
How does non-target tissue biodistribution data impact the overall toxicology program?
This data directly informs the toxicology program. It identifies tissues and organs with unintended exposure, guiding the focus of histology evaluations in toxicology studies. Understanding where the LNP and mRNA payload accumulate allows for the proactive assessment of potential off-target effects and informs the selection of appropriate safety monitoring parameters for first-in-human trials.
What is the regulatory expectation for biodistribution data in an IND submission?
Regulatory agencies expect a comprehensive characterization of the therapeutic’s distribution, persistence, and clearance. The NHP biodistribution data forms a key part of the preclinical safety package, providing the rationale for the selected first-in-human dose and the clinical safety monitoring plan. It demonstrates a thorough understanding of the test article’s in vivo behavior beyond the intended site of action.
